VEXAS syndrome is a rare adult-onset inflammatory disease linked to bone-marrow mutations. Doctors explain why it is often ...

The designation applies to investigational therapies that target rare diseases affecting less than 200,000 people in the US.

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...

New immune roadmaps help physicians detect cancer recurrence early and customize treatments to the body’s defenses, providing ...

Stem cell treatment targeting the bone beneath the knee reduced pain and improved movement more effectively than joint ...

The map was developed by using single-cell RNA sequencing to analyze 1.4 million plasma and immune cells in bone marrow from over 300 patients.

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Surrounded by family and friends, Lane rang the bell, which symbolizes the end of cancer treatments, at Brenner Children’s ...

January 21, 2026-- Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology th ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the condition. UCSF researchers have adapted innovative tools and ...

A growing movement of technically sophisticated patients are channeling their diagnoses into AI systems that address gaps ...